Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

The New Normal: Strategies for the Management of DME in the Age of COVID & Beyond

By: Christina Y. Weng, MD, MBA (Program Moderator); Sophie J. Bakri, MD; Maria H. Berrocal, MD; Sumit Sharma, MD

Webinar Credits: 1.5

Managing patients with retinal diseases is never simple, but with the COVID-19 pandemic, this challenge has become even more difficult as ophthalmologists are struggling to provide the best treatment while limiting office visits. Longer duration therapies are helping to meet those needs.

This webinar will focus on the latest data in diabetic macular edema treatment, comparing clinical trial versus real-world strategies, and the panel will discuss ways to adapt patient care in the COVID-19 era.

This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with diabetic macular edema.

Expiration Date: Tuesday, August 31, 2021
Release Date: August 13, 2020

Learning Objectives

Upon completion of this activity, the learner should be able to:

  • Recognize the advantages and disadvantages of anti-VEGF therapy for patients with diabetic macular edema (DME).
  • Assess the role of sustained release therapies in the treatment of patients with DME as a means of decreasing patient burden.
  • Compare appropriate treatments to maximize outcomes.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Faculty:

 

Christina Y. Weng, MD, MBA

Program Moderator

Associate Professor
of Ophthalmology

Baylor College of Medicine

Houston, Texas

 

 

Sophie J. Bakri, MD

Professor of Ophthalmology

Mayo Clinic

Rochester, Minnesota

 

 

Maria H. Berrocal, MD

Director

Berrocal & Associates

San Juan, Puerto Rico

 

 

Sumit Sharma, MD
Assistant Professor, Ophthalmology

Cleveland Clinic Lerner College
of Medicine

Case Western Reserve University Staff in Vitreoretinal Surgery
and Uveitis

Cleveland Clinic Cole Eye

Cleveland, Ohio

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Christina Weng, MD, MBA and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Alimera Sciences, Allergan, and Novartis.

Sophie J. Bakri, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant:  Adverum, Allegro, Allergan, Alimera Sciences, Eyepoint, Kala, Oxurion, Novartis, and Roche. Grant/Research Support: Lowey Medical Foundation and NIH.

Maria H. Berrocal, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Alimera Sciences, and Allergan. Speaker’s Bureau: Alcon, Alimera, Allergan and Quantel.

Sumit Sharma, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alimera Sciences, Allergan, Bausch + Lomb, Clearside, EyePoint, Genentech/Roche, and Regeneron.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Alimera Sciences.

Pretest

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident

Video Resources

Next

Test

Instructions

Step 1 of 2

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident
  • AgreeNeutralDisagree
    Recognize the advantages and disadvantages of anti-VEGF therapy for patients with diabetic macular edema (DME).
    Assess the role of sustained release therapies in the treatment of patients with DME as a means of decreasing patient burden.
    Compare appropriate treatments to maximize outcomes.
Back